Diabetes Research and Clinical Practice
Volume 87, Issue 1 , Pages 33-37 , January 2010

Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases?

  • Mohammad Kazemi Arababadi

      Affiliations

    • Dept. of Microbiology, Hematology and Immunology, Faculty of Medicine, Rafsanjan University of Medical Science, Rafsanjan, Iran
    • Corresponding Author InformationCorresponding author at: Dept. of Microbiology and Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Tel.: +98 3915234003–5; fax: +98 3915225209.
    • ,
  • Reza Nosratabadi

      Affiliations

    • Dept. of Laboratory Sciences, Faculty of Medicine, Islamic Azad University, Zahedan Branch, Zahedan, Iran
    • ,
  • Gholamhossein Hassanshahi

      Affiliations

    • Dept. of Microbiology, Hematology and Immunology, Faculty of Medicine, Rafsanjan University of Medical Science, Rafsanjan, Iran
    • ,
  • Narges Yaghini

      Affiliations

    • Dept. of Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Science, Rafsanjan, Iran
    • ,
  • Vahid Pooladvand

      Affiliations

    • Dept. of Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Science, Rafsanjan, Iran
    • ,
  • Ali Shamsizadeh

      Affiliations

    • Dept. of Physiology, Faculty of Medicine, Rafsanjan University of Medical Science, Rafsanjan, Iran
    • ,
  • Hamid Hakimi

      Affiliations

    • Dept. of Microbiology, Hematology and Immunology, Faculty of Medicine, Rafsanjan University of Medical Science, Rafsanjan, Iran
    • ,
  • Reza Derakhshan

      Affiliations

    • Ali-Ebne Abitaleb Hospital, Rafsanjan University of Medical Science, Rafsanjan, Iran

Received 2 May 2009 ,Revised 23 September 2009 ,Accepted 28 September 2009.

References 

  1. Steyn NP, Lambert EV, Tabana H. Nutrition interventions for the prevention of type 2 diabetes. Proc. Nutr. Soc. 2008;10:1–16
  2. Arababadi MK, Naghavi N, Hassanshahi G, Mahmoodi M. Is CCR5-Delta32 mutation associated with diabetic nephropathy in type 2 diabetes?. Ann. Saudi Med. 2009;29(5):413
  3. Nathanson D, Nystrom T. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium. Mol. Cell. Endocrinol. 2008;21:21
  4. Cruz M, Maldonado-Bernal C, Mondragon-Gonzalez R, Sanchez-Barrera R, Wacher NH, Carvajal-Sandoval G, et al. Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. J. Endocrinol. Invest. 2008;31(8):694–699
  5. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile, 1,25-dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res. Clin. Pract. 2007;77(1):47–57
  6. Tsiavou A, Degiannis D, Hatziagelaki E, Koniavitou K, Raptis SA. Intracellular IFN-gamma production and IL-12 serum levels in latent autoimmune diabetes of adults (LADA) and in type 2 diabetes. J. Interferon Cytokine Res. 2004;24(7):381–387
  7. Skopinski P, Rogala E, Duda-Krol B, Lipinska A, Sommer E, Chorostowska-Wynimko J, et al. Increased interleukin-18 content and angiogenic activity of sera from diabetic (type 2) patients with background retinopathy. J. Diabetes Complications. 2005;19(6):335–338
  8. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000;67(3):291–300
  9. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002;8(5):500–508
  10. Bever CT, Panitch HS, Levy HB, McFarlin DE, Johnson KP. Gamma-interferon induction in patients with chronic progressive MS. Neurology. 1991;41(7):1124–1127
  11. Wong CK, Ho AW, Tong PC, Yeung CY, Kong AP, Lun SW, et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin. Exp. Immunol. 2007;149(1):123–131
  12. Xie HF, Li J, Shi W. Effect of corticosteroids on the balance of Th cytokines in patients with systemic lupus erythematosus. Hunan Yi Ke Da Xue Xue Bao. 2002;27(6):533–535
  13. Matsumoto K, Kanmatsuse K. Increased urinary excretion of interleukin-17 in nephrotic patients. Nephron. 2002;91(2):243–249
  14. Seconi J, Watt V, Ritchie DS. Nephrotic syndrome following allogeneic stem cell transplantation associated with increased production of TNF-alpha and interferon-gamma by donor T cells. Bone Marrow Transplant. 2003;32(4):447–450
  15. Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB, et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J. Immunol. 1999;162(1):577–584
  16. Hoerbelt R, Benjamin CL, Shoji T, Houser SL, Muniappan A, Hasse RS, et al. The effects of tolerance on allograft damage caused by the innate immune system. Transplantation. 2008;85(3):314–322
  17. Litonjua AA, Sparrow D, Guevarra L, O’Connor GT, Weiss ST, Tollerud DJ. Serum interferon-gamma is associated with longitudinal decline in lung function among asthmatic patients: the Normative Aging Study. Ann. Allergy Asthma Immunol. 2003;90(4):422–428
  18. Cooke A. Th17 cells in inflammatory conditions. Rev. Diabet. Stud. 2006;3(2):72–75
  19. Ozer G, Teker Z, Cetiner S, Yilmaz M, Topaloglu AK, Onenli-Mungan N, et al. Serum IL-1, IL-2, TNFalpha and INFgamma levels of patients with type 1 diabetes mellitus and their siblings. J. Pediatr. Endocrinol. Metab. 2003;16(2):203–210
  20. Chen J, Liu X. The role of interferon gamma in regulation of CD4+ T-cells and its clinical implications. Cell Immunol. 2009;254(2):85–90
  21. Arababadi MK, Pourfathollah AA, Daneshmandi S, Hassanshahi G, Zarandi ER, Shamsizadeh A, et al. Evaluation of relation between IL-4 and IFN-g polymorphisms and type 2 diabetes. IJBMS. 2009;12(2):100–104
  22. Mavridis G, Souliou E, Diza E, Symeonidis G, Pastore F, Vassiliou AM, et al. Inflammatory cytokines in insulin-treated patients with type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 2008;18(7):471–476
  23. Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism. 2003;52(5):605–608
  24. Xu H, Nakayama K, Ogawa S, Sugiura A, Kato T, Sato T, et al. Elevated plasma concentration of IP-10 in patients with type 2 diabetes mellitus. Nippon Jinzo Gakkai Shi. 2005;47(5):524–530
  25. Miljkovic D, Cvetkovic I, Momcilovic M, Maksimovic-Ivanic D, Stosic-Grujicic S, Trajkovic V. Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells. Cell. Mol. Life Sci. 2005;62(22):2658–2668
  26. Mensah-Brown EP, Shahin A, Al-Shamisi M, Wei X, Lukic ML. IL-23 leads to diabetes induction after subdiabetogenic treatment with multiple low doses of streptozotocin. Eur. J. Immunol. 2006;36(1):216–223
  27. Sumarac-Dumanovic M, Stevanovic D, Ljubic A, Jorga J, Simic M, Stamenkovic-Pejkovic D, et al. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int. J. Obes. (Lond.). 2009;33(1):151–156

PII: S0168-8227(09)00419-7

doi: 10.1016/j.diabres.2009.09.027

Diabetes Research and Clinical Practice
Volume 87, Issue 1 , Pages 33-37 , January 2010

Article Tools

* Image Usage & Resolution